Abstract
We are currently experiencing a key period in the management of patients with relapsing remitting multiple sclerosis. The application of new criteria allows early diagnosis, thus at a stage when the available immune treatments are the most likely to show a good efficacy. The therapeutic offer is expanding but its complexity too. It is thus important, for a given patient, to assess as precisely as possible the degree of severity of his/her disease, in order to give the drug with the optimal risk/benefit ratio.
MeSH terms
-
Adjuvants, Immunologic / therapeutic use
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Choice Behavior
-
Combined Modality Therapy
-
Fingolimod Hydrochloride
-
Humans
-
Immunosuppressive Agents / therapeutic use
-
Immunotherapy
-
Multiple Sclerosis / drug therapy
-
Multiple Sclerosis / therapy*
-
Natalizumab
-
Patient Education as Topic
-
Propylene Glycols / therapeutic use
-
Sphingosine / analogs & derivatives
-
Sphingosine / therapeutic use
-
Therapies, Investigational / methods
-
Therapies, Investigational / statistics & numerical data
Substances
-
Adjuvants, Immunologic
-
Antibodies, Monoclonal, Humanized
-
Immunosuppressive Agents
-
Natalizumab
-
Propylene Glycols
-
Fingolimod Hydrochloride
-
Sphingosine